OR WAIT null SECS
Dr Paul Hahn and Dr Michael Cohen explore upcoming treatments featuring innovative mechanisms of action and novel delivery systems for addressing neovascular AMD.
To watch the video series component of this episode, click here.
1:00 Retina specialists’ wish list for innovative therapies
6:40 Home OCT
8:43 Extending treatment intervals beyond four months
9:40 Therapies in the pipeline
15:00 Need for long-term retinal fluid suppression
16:00 Gene therapy
22:00 Helping patients facing end-stage vision loss